PVI
CARM

Pura Vida Investments’s Carisma Therapeutics CARM Stock Holding History

Pura Vida Investments’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,000
Closed -$284K – 109
2018
Q4 		$284K Buy
+10,000
New +$319K 0.06% 67

Other funds holding CARM

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pura Vida Investments's CARM Position: Q1 2019 in Review

Pura Vida Investments sold out of Carisma Therapeutics (CARM) in Q1 2019, closing a stake of 10,000 shares — an estimated $284K sold.

Pura Vida Investments first reported a position in CARM in Q4 2018 and held it in 1 quarter. The position peaked at $284K in Q4 2018. 48 funds tracked by Wall St. Rank hold CARM as of Q1 2019.

  • Pura Vida Investments reported no remaining Carisma Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Pura Vida Investments sold 10,000 Carisma Therapeutics shares in Q1 2019, an estimated $284K.
  • Pura Vida Investments first reported a position in Carisma Therapeutics in Q4 2018 and held it in 1 quarter.
  • Pura Vida Investments's Carisma Therapeutics position peaked at $284K in Q4 2018.
  • 48 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2019.

Based on Pura Vida Investments's 13F filing for Q1 2019, filed 14 May 2019.